Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based Daiichi Sankyo (TYO: 4568) focused on the development and commercialization of three potential first-in-class deruxtecan-based antibody-drug conjugate (ADC) candidates. This partnership aims to advance innovative treatments for various types of cancer.
ADC Candidates and Development Stages
The collaboration encompasses patritumab deruxtecan, which is currently in Phase II for EGFR-mutated non-small cell lung cancer (NSCLC); ifinatamab deruxtecan, a Phase II candidate for small cell lung cancer (SCLC); and raludotatug deruxtecan, which is in the early stages of development for ovarian cancer. These ADCs represent a promising approach to cancer treatment, combining the targeting capabilities of antibodies with the potency of cytotoxic drugs.
Financial Terms of the Collaboration
Under the terms of the agreement, Daiichi Sankyo will receive an upfront payment of USD 1 billion from MSD, plus an additional USD 1.5 billion for each program. Furthermore, Daiichi is eligible to receive up to USD 5.5 billion per molecule in milestone payments, reflecting the significant potential of these ADC candidates.-Fineline Info & Tech
